TABLE 7

Mean pharmacokinetic parameters for NVR 3-778 in mouse plasma following twice-daily oral gavage for up to 28 daysb

DayDose level
(mg/kg/dose)
SexCmax (ng/ml)Tmaxa (h)AUC0–12
(ng⋅h/ml)
t1/2 (h)
150M12,7001.0070,400NC
F11,7000.50060,1002.20
150M25,3001.00166,0005.00
F22,0000.500131,0004.35
500M43,0001.00406,000NC
F41,4000.500315,000NC
2850M11,9003.0087,300NC
F11,5003.0078,800NC
150M24,2001.00157,000NC
F26,6001.00171,0002.48
500M43,8003.00375,0003.15
F40,8003.00354,000NC
  • a Time is relative to the second daily dose.

  • b F, female; M, male; AUC0–12, area under the concentration-time curve from 0 to 12 h after the second daily dose; Cmax, maximum plasma concentration (the lower limit of quantification was 65.0 ng/ml); NC, not calculable; t1/2, half-life; Tmax, time to maximum plasma concentration.